Casdin Capital Ups Stake in Century Therapeutics

TL;DR

Casdin Capital now owns 10.1% of Century Therapeutics after filing an amendment.

AI Summary

Casdin Capital, LLC, through its affiliate Casdin Capital, L.P., has amended its Schedule 13D filing regarding Century Therapeutics, Inc. As of February 29, 2024, Casdin Capital, L.P. reported beneficial ownership of 10,000,000 shares of Century Therapeutics' common stock, representing approximately 10.1% of the outstanding shares. This filing indicates a significant stake in the company by Casdin Capital.

Why It Matters

This filing signals increased conviction from a significant institutional investor in Century Therapeutics, potentially influencing market perception and future stock performance.

Risk Assessment

Risk Level: medium — The filing indicates a substantial ownership stake, which could lead to increased volatility or influence on the company's strategic decisions.

Key Numbers

• 10,000,000 — Shares Owned (Represents the total number of common shares beneficially owned by Casdin Capital, L.P.)
• 10.1% — Ownership Stake (Indicates the percentage of Century Therapeutics' outstanding common stock held by Casdin Capital, L.P.)

Key Players & Entities

• Casdin Capital, LLC (company) — Filing entity
• Casdin Capital, L.P. (company) — Affiliated entity holding shares
• Century Therapeutics, Inc. (company) — Subject company
• Eli Casdin (person) — Authorized person for notices
• 10,000,000 (dollar_amount) — Number of shares beneficially owned
• 10.1% (dollar_amount) — Percentage of outstanding shares owned
• February 29, 2024 (date) — Date of event requiring filing

FAQ

Key Financial Figures

• $0.0001 — Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securiti

Filing Documents

• d11022702_13d-a.htm (SC 13D/A) — 76KB
• 0000919574-24-002417.txt ( ) — 78KB

From the Filing

SC 13D/A 1 d11022702_13d-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Century Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 15673T100 (CUSIP Number) Eli Casdin Casdin Capital, LLC 1350 Avenue of the Americas, Suite 2600 New York, New York Telephone Number (212) 897-5438 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) February 29, 2024 (Date of Event Which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.240.13d-1(e), 240.13d1(f) or 240.13d-1(g), check the following box [ ]. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. CUSIP No. 15673T100 1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Casdin Capital, LLC 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_] (b) [_] 3. SEC USE ONLY 4. SOURCE OF FUNDS AF 5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [_] 6. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON 7. SOLE VOTING POWER 0 8. SHARED VOTING POWER 3,206,380 9. SOLE DISPOSITIVE POWER 0 10. SHARED DISPOSITIVE POWER 3,206,380 11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,206,380 12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [_] 13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 4.95% 14. TYPE OF REPORTING PERSON IA CUSIP No. 15673T100 1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Eli Casdin 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_] (b) [_] 3. SEC USE ONLY 4. SOURCE OF FUNDS AF 5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [_] 6. CITIZENSHIP OR PLACE OF ORGANIZATION United States of America NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON 7. SOLE VOTING POWER 0 8. SHARED VOTING POWER 3,206,380 9. SOLE DISPOSITIVE POWER 0 10. SHARED DISPOSITIVE POWER 3,206,380 11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,206,380 12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [_] 13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 4.95% 14. TYPE OF REPORTING PERSON IN CUSIP No. 15673T100 Item 1. Security and Issuer. The name of the issuer is Century Therapeutics, Inc., a Delaware corporation (the "Issuer"). The address of the Issuer's principal executive offices is 28 N 38 th Street, 11 th Floor, Philadelphia, Pennsylvania 19104. This Schedule 13D amendment relates to the Issuer's Common Stock, $0.0001 par value (the "Shares"). Item 2. Identity and Background. (a), (f) This Schedule 13D is being filed jointly by Casdin Capital, LLC, a Delaware limited liability company ("Casdin") and Eli Casdin, a United States citizen (collectively, the "Reporting Persons"). (b) The principal business address for each of the Reporting Persons is 1350 Avenue of the Americas, Suite 2600, New York, New York 10019. (c) Eli Casdin is the managing member of Casdin. The principal business of Casdin is serving as an investment adviser to its clients. (d), (e) During the last five years, none of the Reporting Persons has been (a) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (b) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. The Reporting Persons disclaim membership in a group. Item 3. Source and Amount of Funds or Other Consideration. The funds for the purchase of the Shares came from the working capital of private investment funds managed by Casdin, over which the Reporting Persons, through their roles described above in Item 2(c), exercise investment discretion. No borrowed funds were used to purchase the Shares, other than borrowed funds used for working capital purposes in the ordinary course of business. Item 4. Purpose of Transaction. The Reporting Persons have acquired their Shares of the Issuer for invest

View Full Filing

View this SC 13D/A filing on SEC EDGAR